# GALAHAD (niraparib): what clinicians are saying

> 272 statements from 18 sources (5 podcasts, 2 videos, 8 posts, 2 papers, 1 registry record), 95 of them from 12 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026.

## Report

- Trial: A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
- NCT ID: NCT02854436
- Registry: https://clinicaltrials.gov/study/NCT02854436
- Sponsor: Janssen Research & Development, LLC
- Phase: Phase 2
- Status: Completed
- Drugs tested: niraparib
- Indication: metastatic castration-resistant prostate cancer with DNA-repair gene defects
- Version: v1.0.0, edition 1
- Accepted: 2026-11-19 UTC
- Last checked: 2026-11-19 UTC
- Release hash: bb34f6aa728d2d4fd7240e480cee246d8c587720b781854a429bc49b32a1708f

## Counts

- Commentary sources screened: 66
- Sources cited by verified statements: 18
- Verified statements: 272
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 95
- Findings: 10
- Named people in screened sources (unnamed speakers and accounts not counted): 21
- Speakers cited: 20
- Cited speakers with a verified identity: 16
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 12
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 11
- By role and specialty (the abstract's specialty counts):
  - 8 physician, Medical oncology
  - 2 physician, specialty not confirmed
  - 1 nurse practitioner
  - 1 physician, Urology

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

Speakers interpret GALAHAD as supporting BRCA1/2-based selection because responses were less frequent with other alterations, with an explicit caution in discussion against inferring a survival improvement. Niraparib’s relative benefit drew tentative doubt in one discussion, whereas another speaker found no benefit-based reason to favor one PARP inhibitor over another. A medical oncologist requested comparative evidence; small groups with rarer alterations also leave their potential benefit uncertain.

## Question clinicians left open

What do clinicians still need to see on gene-specific responses to define niraparib monotherapy’s role beyond BRCA1/2 alterations in metastatic castration-resistant prostate cancer after androgen-signaling inhibitors and taxanes, particularly for ATM, CDK12 and rarer DNA-repair alterations?

From finding F1 (20 statements from 3 speakers in 8 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. GALAHAD by gene: what a speaker highlights in BRCA benefit and non-BRCA uncertainty
  - 20 statements from 3 speakers in 8 sources, 5 of them podcasts or videos.
  - 1 of the 3 named speakers in this finding holds this view.
  - 1 of the report's 12 cited clinicians.
- F2. PARP inhibitors: where speakers split on whether efficacy can be ranked
  - 20 statements from 5 speakers in 10 sources, 7 of them podcasts or videos.
  - 3 of the 5 named speakers in this finding take a side on this question.
  - 3 of the report's 12 cited clinicians.
- F3. Niraparib toxicity: a speaker describes it as class-consistent and highlights anemia
  - 7 statements in 2 sources, 1 of them a podcast or video.
  - No named speaker is counted in this finding: its title's view comes from speakers the source does not name.
  - No named clinician · accounts and unnamed speakers.

### Beyond the trial population

- F4. HRR testing: most speakers prioritize it; some see assay and prediction gaps
  - 72 statements from 12 speakers in 10 sources, 5 of them podcasts or videos.
  - 7 of the 12 named speakers in this finding hold this view; 6 of the 12 hold its caveat, “some see assay and prediction gaps”.
  - 8 of the report's 12 cited clinicians.
- F5. PARP safety: how speakers weigh symptom control against long-term concerns
  - 35 statements from 8 speakers in 5 sources, all podcasts or videos.
  - 0 of the 8 named speakers in this finding take a side on this question: 0 on one side, 0 on the other.
  - 5 of the report's 12 cited clinicians.
- F6. Carboplatin: some speakers consider it if PARP access fails but lack head-to-head data
  - 16 statements from 5 speakers in 4 sources, 3 of them podcasts or videos.
  - 2 of the 5 named speakers in this finding hold this view; 2 of them hold its caveat, “lack head-to-head data”.
  - 3 of the report's 12 cited clinicians.
- F7. 1L mCRPC PARP combos: how speakers weigh biomarkers, prior therapy and access
  - 42 statements from 6 speakers in 5 sources, 4 of them podcasts or videos.
  - 5 of the 6 named speakers in this finding take a side on this question.
  - 5 of the report's 12 cited clinicians.
- F8. PARP failure: what speakers say
  - 11 statements from 3 speakers in 3 sources, 2 of them podcasts or videos.
  - 3 of the report's 12 cited clinicians.
- F9. BRCA-mutated, MSI-high prostate cancer: what speakers say
  - 9 statements from 3 speakers in 1 source, a podcast or video.
  - 3 of the report's 12 cited clinicians.
- F10. Molecularly informed prostate cancer care: most speakers support genetic counseling
  - 23 statements from 5 speakers in 5 sources, 4 of them podcasts or videos.
  - 3 of the 5 named speakers in this finding hold this view.
  - 2 of the report's 12 cited clinicians.

7 of the 10 findings and 201 of the 272 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 20 | 17 | 8 | 3 | 3 |
| F2 | 20 | 21 | 10 | 5 | 4 |
| F3 | 7 | 6 | 2 | 0 | 3 |
| F4 | 72 | 49 | 10 | 12 | 4 |
| F5 | 35 | 31 | 5 | 8 | 4 |
| F6 | 16 | 13 | 4 | 5 | 3 |
| F7 | 42 | 30 | 5 | 6 | 4 |
| F8 | 11 | 10 | 3 | 3 | 3 |
| F9 | 9 | 4 | 1 | 3 | 4 |
| F10 | 23 | 12 | 5 | 5 | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 8 | 2 | 1 | 3 | 6 | 23 | 6 | 2 posts and articles, 5 podcasts and video, 1 publication |
| F2 | 6 | 5 | 0 | 4 | 5 | 22 | 5 | 2 posts and articles, 7 podcasts and video, 1 publication |
| F3 | 3 | 0 | 0 | 2 | 2 | 9 | 0 | 1 podcast or video, 1 publication |
| F4 | 39 | 9 | 9 | 1 | 14 | 79 | 5 | 4 posts and articles, 5 podcasts and video, 1 publication |
| F5 | 15 | 8 | 5 | 1 | 6 | 40 | 5 | 5 podcasts and video |
| F6 | 6 | 6 | 2 | 1 | 1 | 17 | 5 | 1 post or article, 3 podcasts and video |
| F7 | 26 | 6 | 2 | 4 | 4 | 45 | 0 | 4 podcasts and video, 1 publication |
| F8 | 7 | 3 | 1 | 0 | 0 | 11 | 1 | 2 podcasts and video, 1 publication |
| F9 | 5 | 1 | 2 | 0 | 1 | 9 | 0 | 1 podcast or video |
| F10 | 13 | 0 | 9 | 0 | 1 | 24 | 0 | 1 post or article, 4 podcasts and video |

### Trial dimensions

- Primary endpoint: Objective Response Rate (ORR) for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Breast Cancer Gene (BRCA) Mutation: F1 (6 shared claims), F2 (1 shared claims)
- Secondary endpoints: F1 (2 shared claims)
- Population and setting: F1 (11 shared claims)
- The comparison: F1 (4 shared claims), F2 (8 shared claims)
- Safety and tolerability: F3 (1 shared claims)
- Design and conduct: F1 (5 shared claims)

## Abbreviations

- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- MSI: microsatellite instability
- NPI: National Provider Identifier, the US registry number for clinicians
- ORR: objective response rate
- PARP: poly(ADP-ribose) polymerase

## Examples from the report

Statements as the report records them, by the speaker's role only. Full statements, speaker names and links to each source are in the report.

- Medical oncologist, ex-US, identity checked against a staff page · podcast · Jun 2025 (finding F2): A medical oncologist includes GALAHAD among the PARP-inhibitor monotherapy studies that provided the basis for current single-agent indications in prostate cancer.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 10 | Titles free |
| Detailed analysis | 12 sections | Paid |
| Verified statements with short source quotes and links | 272 | Paid |
| Who said each statement: the cited speakers | 20 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 12 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 16 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 14 | Free |
| Sources with links | 18 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 12 of the 20 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

14 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Objective Response Rate (ORR) for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Breast Cancer Gene (BRCA) Mutation | discussed | 6 | 4 |
| Secondary endpoints | discussed | 2 | 1 |
| Population and setting | discussed | 11 | 6 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 12 | 7 |
| Safety and tolerability | discussed | 5 | 5 |
| Design and conduct | discussed | 5 | 3 |
| Molecular selection, alteration type and testing access | discussed | 67 | 9 |
| Agent differentiation and time-specific regulatory context | discussed | 18 | 9 |
| Class safety, individualized management and delayed harms | discussed | 35 | 5 |
| Platinum alternatives, affordability and comparative evidence | discussed | 16 | 4 |
| Earlier combination choices and reasons to defer broader use | discussed | 41 | 4 |
| Response waiting, progression and subsequent treatment | discussed | 9 | 2 |
| Coexisting BRCA and MSI findings as an alternative-treatment question | discussed | 9 | 1 |
| Patient understanding, nursing support and genetic counseling | discussed | 23 | 5 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 220 statements · 81%** | | | |
| YouTube | 51 | 2 | 2 |
| X videos | 0 | 0 | 1 |
| Podcasts | 169 | 5 | 5 |
| **Posts · 17 statements · 6%** | | | |
| X threads | 17 | 8 | 56 |
| LinkedIn posts | 0 | 0 | 1 |
| Bluesky threads | 0 | 0 | 1 |
| **Primary sources · 35 statements · 13%** (cited for context, not screened) | | | |
| Publications (primary source, cited for context) | 33 | 2 | not screened |
| Registry (primary source, cited for context) | 2 | 1 | not screened |

- Screened window: 2018-02-08 to 2026-10-04
- Cited window: 2018-09-18 to 2025-06-16
- Retrieved: 2026-11-18

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
- Registry: NCT02854436 (https://clinicaltrials.gov/study/NCT02854436)
- Study IDs: CR108208 · 64091742PCR2001 (Janssen Research & Development, LLC) · 2016-002057-38
- Sponsor: Janssen Research & Development, LLC
- Design: Phase 2 · interventional, na, single group, phase2
- Status: Completed
- Enrollment: 289 (actual)
- Start: 2016-08-31 (actual)
- Primary completion: 2021-01-26 (actual)
- Primary endpoint: Objective Response Rate (ORR) for Participants With Measurable Metastatic Castration-resistant Prostate Cancer (mCRPC) and Breast Cancer Gene (BRCA) Mutation (Up to 52 months)
- Intervention: Niraparib (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 1 cited commentary passage leaves a source question open, such as who was speaking. The report attributes no further than the source shows.
- Not yet captured in this edition: a view on assessment methods, mutation-defined benefit and survival uncertainty with PARP inhibition in metastatic castration-resistant prostate cancer; a view on biomarker selection and comparator choices for PARP-inhibitor treatment in DNA-repair–altered metastatic castration-resistant prostate cancer; a view on genetic testing, patient selection and evidence beyond scans when weighing PARP inhibition; a view on PARP inhibitor efficacy in BRCA-mutated metastatic castration-resistant prostate cancer; a view on having to defer treatment until castration resistance if approval is restricted to that setting; a view on assessment methods and mutation-specific evidence informing treatment selection in metastatic castration-resistant prostate cancer; a view on biomarker-guided selection and reasons to withhold PARP inhibition in metastatic castration-resistant prostate cancer; a view on how BRCA and other DNA-repair alterations qualify interpretation of progression and survival evidence; a view on interpreting PARP-inhibitor survival evidence in DNA-repair-altered metastatic castration-resistant prostate cancer when crossover occurs; a view on microsatellite instability work-up and immunotherapy selection in BRCA-mutated prostate cancer; a view on distinguishing pulmonary-only from liver metastases when assessing prognosis in metastatic castration-resistant prostate cancer.
- 2 passages in 1 source used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 259 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 18 sources about other trials or topics are not included.
- ClinicalTrials.gov first posted results for the trial on 8 March 2022.
- The sources reviewed include historical remarks from 2018 through June 2025. Approval, reimbursement, enrollment and anticipated-study statements retain their discussion timing and do not describe current universal availability.
- This is a qualitative selection of public discussion, not a representative survey. A source count, repeated panel remarks, reposts or language versions cannot be treated as an independent-HCP count or a consensus measure.
- Some passages do not identify their speakers sufficiently for named attribution. Their views remain attributed to their episodes or discussions rather than assigned from a program roster or neighboring remarks.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Discussions without the trial name or using other wording may be absent. The material reviewed therefore cannot establish the complete public conversation about GALAHAD's clinical question.
- Some relevant portions of the April 2023 episode remain incompletely assessed, including discussion of patient benefit beyond scans, testing, approval and treatment timing. Their absence may affect the balance of practical and patient-centered views.
- Treatment-choice coverage is incomplete: the October 2022 webinar's concluding monotherapy-sequencing assessment and its treatment-history rationale are not fully represented, nor is a speaker's explanation of regional monotherapy approvals. This limits conclusions about preferred sequencing and the evidentiary reasons behind European and US differences.
- The dose-reduction discussion captures a speaker's case-derived generalization, not a detailed patient-level toxicity course. It cannot quantify how often dose adjustment restores tolerability.
- The full text of the separate GALAHAD quality-of-life publication was unavailable. Its abstract supports publication context but not a complete appraisal of that analysis or clinician uptake.
- GALAHAD's nonrandomized cohort comparisons do not establish superiority over another treatment or a causal survival advantage. Cross-trial agent rankings and combination-dose explanations remain attributed, qualified opinions.
- A talk described GALAHAD as involving roughly 50 patients; that is the speaker's approximate description, not the final study enrollment reported in the publication.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-19 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-19 UTC. No changes.

## Offer

- Size: Standard · 272 verified statements · 95 from 12 confirmed clinicians
- Current edition: $1,250. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $2,200
- 6 months of updates: $3,100
- 12 months of updates: $4,400
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (16 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/galahad-nct02854436
- Agents: POST https://www.erudio.com/api/orders with {"report": "galahad-nct02854436", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=galahad-nct02854436

## Cite

Erudio Health. GALAHAD (NCT02854436): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 19, 2026. https://www.erudio.com/reports/galahad-nct02854436

## Questions

### How much does the GALAHAD report cost?

One edition costs $1,250 (Standard · 272 verified statements · 95 from 12 confirmed clinicians). With updates: 3 months $2,200, 6 months $3,100, 12 months $4,400. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the GALAHAD report cover?

272 statements from 18 sources (5 podcasts, 2 videos, 8 posts, 2 papers, 1 registry record), 95 of them from 12 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the GALAHAD report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "galahad-nct02854436" }) previews it and create_order({ "report": "galahad-nct02854436", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the GALAHAD report?

Edition 1 (version 1.0.0), accepted Nov 19, 2026 UTC; last checked for new commentary Nov 19, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/galahad-nct02854436.json
- Markdown: https://www.erudio.com/reports/galahad-nct02854436.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/galahad-nct02854436/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "galahad-nct02854436"}`
